Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatr Transplant ; 22(5): e13220, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29777573

RESUMO

Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV-specific T-cell immunity is associated with control and protection against CMV. The clinical utility of monitoring CMV-specific CMI to predict CMV viremia in pediatric HSCT patients using the Quantiferon-CMV (QIAGEN® ) test was investigated prospectively. Thirty-seven pediatric allogeneic HSCT recipients were enrolled from 3/2010-6/2012. CMV viremia was detected via weekly real-time PCR. The Quantiferon-CMV test was conducted pretransplant, early after transplantation, 30, 90, 180, 270, and 360 days post-transplantation. The incidence of CMV viremia was 51% (19/37) with half of the episodes within ≤30 days post-transplant. Fifteen patients showed CMV-specific immunity (average of 82 days). The cumulative incidence of CMV reactivation in patients who developed CMV-specific immunity was lower than those who did not (15% vs 53%; P = .023). The ROC statistical analysis showed that the AUC was 0.725 in predicting viremia, for Quantiferon-CMV test. In this cohort, the Quantiferon-CMV assay was a valuable method for identifying pediatric HSCT patients at high risk for CMV viremia, suggesting potential clinical utility to individualize patient's management post-transplant.


Assuntos
Linfócitos T CD8-Positivos/imunologia , Infecções por Citomegalovirus/diagnóstico , Citomegalovirus/imunologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Imunidade Celular , Viremia/diagnóstico , Adolescente , Criança , Pré-Escolar , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/imunologia , Feminino , Humanos , Lactente , Estudos Longitudinais , Masculino , Estudos Prospectivos , Reação em Cadeia da Polimerase em Tempo Real , Viremia/imunologia
2.
Pediatr Transplant ; 11(7): 799-803, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17910661

RESUMO

PNP deficiency is an autosomal recessive metabolic disorder characterized by severe combined immunodeficiency, autoimmune hemolytic anemia, and by a complex of neurologic manifestations including ataxia, developmental delay, and spasticity. PNP protein catalyzes the phosphorolysis of deoxyinosine and deoxyguanosine. It is found in most tissues of the body but is expressed at the highest levels in lymphoid tissues. This tissue distribution explains why the lymphoid system is predominantly affected in PNP deficiency. We describe a five-yr-old boy with muscular hypertonia, impaired growth, autoimmune hemolytic anemia, and neutropenia who underwent HSCT from his HLA-identical sister. One yr post-HSCT, the boy developed normal immunological functions, and his neurological status improved.


Assuntos
Anemia/terapia , Antígenos HLA/imunologia , Transplante de Células-Tronco Hematopoéticas , Purina-Núcleosídeo Fosforilase/deficiência , Anemia/etiologia , Anemia/patologia , Biópsia , Pré-Escolar , Feminino , Humanos , Masculino , Irmãos , Doadores de Tecidos , Quimeras de Transplante , Condicionamento Pré-Transplante , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...